RenovaCare Appoints Dr. Lydia M. Evans to Its Board of Directors and Increases Board Membership – GlobeNewswire

Posted: August 5, 2020 at 9:54 am

Dr. Lydia M. Evans, MD

Dr. Lydia M. Evans, Director, RenovaCare, Inc.

ROSELAND, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR;www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced the appointment of Lydia M. Evans, M.D. to its Board of Directors. A noted dermatologist, oncologist, and doctor of internal medicine, Dr. Evans has held numerous academic, private, and commercial appointments, and brings extensive insights into the science, technology, and market positioning of wound and skin regeneration therapies.

As RenovaCare continues to advance our portfolio of regenerative technologies, strategic leadership from our Board is increasingly critical as we look to regulatory approval and commercialization. Dr. Evans knowledge and experience will be a strong addition to our Board at such an important time as the Company continues to pursue bringing first-in-class regenerative therapies to market, stated Alan L. Rubino, RenovaCare CEO & President.

"Im pleased to join the RenovaCare Board of Directors at a time of growing demand for modern therapies that promise natural regeneration for burns, wounds, skin disorders and cosmetic imperfections. The RenovaCare CellMist and SkinGun represent an impressive therapeutic approach that replaces painful and complex skin grafting procedures with a gentle mist of the patients own cells. I look forward to assisting the Company in its development, concluded Dr. Evans.

A Columbia Presbyterian and Memorial Sloan Kettering-educated dermatologist, oncologist and doctor of internal medicine, Dr. Evans specializes in state-of-the-art treatments for aesthetic and medical dermatologic procedures. She is currently an Associate Clinical Attending Physician in the Department of Dermatology at New York Presbyterian Medical Center in New York City, a position which includes significant teaching responsibilities. She is also a Fellow of the American Academy of Dermatology, a Diplomate of the National Board of Medical Examiners, the American Board of Internal Medicine, and the American Board of Dermatology. She is a member of the Leadership Society of the Dermatology Research Foundation and has served as the New York State Chairperson for the Psoriasis Research Foundation. Dr. Evans was Consulting Dermatologist to LOral Paris from 2000 to 2012, spurring new product development in dermatologist-inspired skincare directly to consumers.About RenovaCareRenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the bodys largest organ, the skin. The companys flagship technology, the CellMist System, uses its patented SkinGun to spray a liquid suspension of a patients stem cells the CellMist Solution onto wounds.

RenovaCare is developing its CellMist System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.

RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Companys planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.

For additional information, please call Amit Singh at: 888-398-0202 or visit:https://renovacareinc.com

To receive future press releases via email, please visit:https://renovacareinc.com/investors/register/

Follow us on LinkedIn:https://www.linkedin.com/company/renovacare-inc-/

Follow us on Twitter:https://twitter.com/RenovaCareInc

Follow us on Facebook:https://www.facebook.com/renovacarercar

Social Media DisclaimerInvestors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first.

We encourage investors, the media, and others interested in the company to review the information we post on the companys website and the social media channels listed below:

* This list may be updated from time to time.

Legal Notice Regarding Forward-Looking StatementsNo statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the Company) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words may, will, should, could, expect, anticipate, estimate, believe, intend, or project or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Companys product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Companys technologies, technical problems with the Companys research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Companys operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Companys ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Companys most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission athttp://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Read the original here:
RenovaCare Appoints Dr. Lydia M. Evans to Its Board of Directors and Increases Board Membership - GlobeNewswire

Related Posts

Comments are closed.

Archives